Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series

Movement Disorders

Volumn 22, Issue 12, 2007, Pages 1757-1763

  Gallagher, David A ^a,b   O'Sullivan, Sean S ^b   Evans, Andrew H ^b   Lees, Andrew J ^b   Schrag, Anette ^a,b,c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine disregulation; Gambling; Impulse control disorder; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROSS ALLERGY; DOPAMINERGIC ACTIVITY; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; HUMAN; MALE; MENTAL DISEASE; MONOTHERAPY; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; POPULATION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

EID: 35348966827     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21611     Document Type: Article

References (50)

1. American Psychiatric Association. Diagnostic and Statistical manual of mental disorders, 4th ed. Washington, DC: APA; 2004.
2. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to dopsmine dysregulation syndrome. Mov Disord 2004;19:367-370.
3. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapy. J Neurol Neurosurg Psychiatry 2000;68:423-428.
4. Tyne HL, Medley G, Ghadiali E, Steiger MJ. Gambling in Parkinson's disease. Mov Disord. 2004;19 (Suppl 9):S195.
5. Serrano-Duenas M. Chronic dopamimetic drug addiction and pathologic gambling in patients with Parkinson's disease- presentation of four cases. German J Psychiatry 2002;5:62-66.
6. Antonini A, Siri C, De Gaspari D, et al. Pathological gambling (PG) in Parkinson's disease (PD) during ergot and non-ergot dopamine agonists treatment. Mov Disorder 2006; 21 (Suppl 15): S657.
7. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61:422-423.
8. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson's disease. Arch Neurol 2006;63:969-973.
9. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66:1750-1752.
10. Grosset KA, Macphee G, Guru P, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 2006;21:2206-2208.
11. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006;67:1258-1261.
12. Bland JM, Altman DG. The odds ratio. BMJ 2000;320:1468.
13. Petry NM, Stinson FS, Grant BF. Comorbidity of DSM IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and related conditions. J Clin Psychiatry 2005;66:564-574.
14. Ferris J, Stripe T, Ialomiteanu A. Gambling in Ontario: a report from a general population survey on gambling-related problems and opinions. Toronto: Addiction Research Foundation; 1996.
15. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62: 1377-1381.
16. Larner A. Medical hazards of the internet: Gambling in Parkinson's disease. Mov Disord 2006;21:1789.
17. Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000;11:185-186.
18. Gschwandtner U, Aston J, Renaud S, Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001; 24:170-172.
19. Avanzi M, Uber E, Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 2004;25:98-101.
20. Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord (in press).
21. Spengos K, Grips E, Karachalios G, Tsivgoulis G, Papadimitriou G. Reversible pathological gambling under treatment with pramipexole] Nervenarzt 2006;77:958-960.
22. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524-529.
23. Montastruc JL, Schmitt L, Bagheri H. Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine Rev Neurol (Paris) 2003;159:441-443.
24. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21:1941-1946.
25. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004;19:433-469.
26. Imamura A, Uitti RJ, Wszolek ZK. Dopamine agonist therapy for Parkinson disease and pathological gambling. Parkinson Relat Disord 2006;12:506-508.
27. Drapier D, Drapier S, Sauleau P, et al. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. Psychiatry Res 2006;144:241-244.
28. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006;21:2068.
29. Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease. Arch Neurol 2006;63:298.
30. Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling J Clin Psychopharmacol 2007;27:107-108.
31. Wong SH, Cowen Z, Allen EA, Newman PK. Internet gambling and other pathological gambling in Parkinson's disease: a case series. Mov Disord 2007;22:591-593.
32. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007;64:212-216.
33. Garcia RF, Ordacgi L, Mendlowicz MV, et al. Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling. Cogn Behav Neurol 2007;20:11-14.
34. Smeding HM, Goudriaan AE, Foncke EM, Schuurman PR, Speelman JD, Schmand B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007;78:517-519.
35. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570-1574.
36. Potenza M, Kosten T, Rounsaville B. Pathological gambling. JAMA 2001;286:141-144.
37. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioural manifestation of pharmicologic treatment. Mov Disord 2000;15:869-872.
38. Szarfman A, Doraiswamy PM, Tonning JM, Levine JG. Association between pathologic gambling and Parkinsonian therapy as detected in the Food and Drug Administration adverse event database. Arch Neurol 2006;63:299-300.
39. Reuter J, Raedler T, Rose M, Hand I, Glascher J, Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005;8:147-148.
40. Ouchi Y, Yoshikawa E, Okada H, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for β-CFT binding with positron emission tomography. Ann Neurol 1999;45:601-610
41. Bechara A, Damasio H, Tranel D, Damasio A. The Iowa Gambling Task and the somatic marker hypothesis: Some questions and answers. Trends Cogn Sci 2005;9:159-162.
42. Thiel A, Hilker R, Kessler J, Habedank B, Herholz K, Heiss WD. Activation of basal ganglia loops in idiopathic Parkinson's disease: a PET study. J Neural Transm 2003;110:1289-301.
43. Volkow ND, Wang GJ, Ma Y, et al. Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. J Neurosci 2005;25:3932-3939.
44. Toneatto T, Brennan J. Pathological gambling in treatment-seeking substance abusers. Addict Behav 2002;27:465-469.
45. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-858.
46. Boileau I, Dagher A, Leyton M, et al. Modeling sensitization to stimulants in humans: an [HC]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006;63: 1386-1395.
47. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and MSA. Parkinson Relat Disord 2005;11:381.
48. Sylvain C, Ladouceur R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol 1997;65:727-732.
49. Stewart RM, Brown RI. An outcome study of Gamblers Anonymous. Br J Psychiatry 1988;152:284-288.
50. Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000;47: 813-817.